Voyager Therapeutics' Stock Soars After Parkinson's Disease Treatment's Positive Trial Results

Shares of Voyager Therapeutics Inc. rocketed 35% toward an 11-month high in premarket trade Thursday, after the company reported positive results from an early-stage trial of its treatment for Parkinson's disease. That puts the shares on course to post the biggest one-day gain since they went public on Nov. 11, 2015, at an initial public offering price of $14. The company said late Wednesday that results from a Phase 1b trial showed that escalating doses of VY-AADC01 were well tolerated and produced "clinically meaningful improvements in various measures of patients' motor function." The company said it continues to enroll patients in another study, and remains on track to report six-month data in mid 2017. The stock had tumbled 37% year to date through Wednesday, while the S&P 500 has gained 9.7%.